Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADDING
Chart looks Geert!
Added another 10K just now to my swing position.
Cheers!
CHART LOOKS YUMMY
Swing Time
Cheers!
Yes, thanks for watching on these warrants....we;ll surely see ALL exercised on the form 4's in the following days....2 days after exercise for the insiders!
Yes, thanks for watch on these warrants....we;ll surely see ALL exercised on the form 4's in the following days....2 days after exercise for the insiders!
333,432 warrants at a price of $1.86 with a value of $620,183.52 expire today.
41.67% daily short volume but PPS up 3.56%!
33.15% institutional ownership
41.67% daily short volume on Tuesday but PPS up 3.56%!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 91.2%
Shares available to borrow: 200
41.67% of the daily volume has been shorted on Tuesday but the PPS went up 3.56%! Only 200 shares are currently available for shorting (iborrowdesk) and the borrow fee is 91.2% - as soon as we get some decent volume, the shorts will get a serious problem! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
Nothing will occur in 2022. The cvm MO has never changed, a day late and a dollar short. NWBO is a better bet.
A recent article put these out:
Multikine Near Term Milestones
? Submission of data of clinicaltrials.gov – May 2022
? Presentation of abstract at ASCO – June 2022
? Development of clinical study report – 2022
? Request meeting with FDA to determine path forward – 2022
? Development of paper for publication in peer reviewed journal – 2022
? Presentation of data package to review with FDA – 2022
? Address FDA Comments – 2022
? Submission of BLA to FDA – 2022
The question is can CVM accomplish these milestones by end of year.
I hope so, but past experience says no.
It took them 9 months to submit the data to clinicaltrials.gov. 9 months and they still have to resubmit it twice, if not more.
I’m definitely on the outside looking-in, so they may be working at breakneck speed with perfect execution and I just don’t understand.
But as an investor of over 10 years, going thru two reverse splits and taking tons of flack from family members for investing in this company, my patience has now turned into nerves of steel and their wavering.
CVM says it has funds thru 2023, a lot of it came from my retirement, so no, they don’t need more money or dilution.
They need a quick kick in the pants.
Happy Juneteenth
It’s an important day
Cheers
33.13% daily short volume but PPS up 5.65%!
33.15% institutional ownership
33.13% daily short volume on Friday but PPS up 5.65%!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 73.6%
Shares available to borrow: 100
33.13% of the daily volume has been shorted on Friday but the PPS went up 5.65%! Only 100 shares are currently available for shorting (iborrowdesk) and the borrow fee is 73.6% - as soon as we get some decent volume, the shorts will get a serious problem! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
The exercise price is too low. Would love to see them expire, but that won't happen.
But the company receives cash if the warrants are exercised. So that would be good for the company even if there is small dilution
There were so many to keep track of ..... even after two reverse splits.
It’s nice to see some of the long time posters back! Sab, Park, Lightrock, and others. It’s good to see you guys posting again. Hope things are going well for y’all. I just re-entered in the low 3’s. If you’ve taken a position too, wish us the best of luck!
What a Stinker!!!
Stop loss hit. Made a few thousand. Oh well
Back to $2s?? I’ll revisit next week
Happy Juneteenth!
Ok back to the lake on my new Seadoos
Cheers!!!
Glad you have been tracking the warrants!
I remember very well when I was considered foolish for tracking them as being not important! Especially now those very cheap strikes bear watching.
There is some fairly serious resistance in the $5 to $5.50 area, but still looks attractive to me....good luck!
Bought 23k
Off the the cabin in the Bronco pulling our new jet skis!
Go Cvm!!!!
Cheers.
@ 1,000,000 of them are in the money and are worth about $2,200,000.
I remember when there were 10,000,000 worth $55,000,000. I'll be glad when they are off the books.
To be fair, "$2s" could have been shorthand for = $2 x $2 x $2
Foxwoods
Youre welcome...however, you seem angry.
Cheers!
Thanks for the reminder of an obvious fact.
It definitely helps the newbies sort out those who here has an agenda. The rest of us are well aware.
The 333,432 warrants that expire on June 22 are interesting. They are in the money, but will they be exercised? They are the largest lot from your list. Same for the ones expiring June 30th.
I’m guessing the 120k at $9.25 expiring on July 13th and 26k at $12 expiring on August 15th will expire unless the FDA offers CVM an expedited approval.
The more that expire the better, less dilution.
Shabbat Shalom
I remember when this was $25+. Now $3
Woof!
Coming up on the 1 yr anniversary of Data release.
Cheers
60.09% daily short volume on Thursday
33.15% institutional ownership
60.09% daily short volume on Thursday!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 93.4%
Shares available to borrow: 100
60.09% of the daily volume has been shorted on Thursday! Only 100 shares are currently available for shorting (iborrowdesk) and the borrow fee is 93.4%! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
Not sure about that. According to the short term chart, there may be a decent size move in price before the next fall. I'm thinking maybe as high as $6.50.
Of course at that point, everyone here will be lauding the moon and buying rather than selling.
JMO, of course.
Your post's are the only ones worth reading on this board. Intuitional ownership means a lot. Especially Vanguard. That's who I trade with and my trades are free...Keep your daily posts coming. Tick Tock
45.14% daily short volume but PPS up 6.93%!
33.15% institutional ownership
45.14% daily short volume on Wednesday!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 87.8%
Shares available to borrow: 400
45.14% of the daily volume has been shorted on Wednesday but the PPS went up 6.93!! Only 400 shares are currently available for shorting (iborrowdesk) and the borrow fee is 87.8%! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
Was thinking of buying a cult mask but I’m not that delusional
FASCINATING DAYS AHEAD
One never knows. Some very vocal investors have gone from analysis of prospects and cash flow and looking for every word change in 10-Qs to Clay DayTrader. This company has a history of climbing on very low volume.
I'm not sure about this call? It's almost been a week. Fascinating.
Borrow Fee of 87.8% and Only 100 Shares Available
The current borrow fee is 87.8% and a total of 100 shares are available to be borrowed (as reported by iborrowdesk)!! Just wait until we get some decent volume to see how the desperate shorts will struggle to cover their 9.08 million shares (21.8% of the float). GLTAL! Tick tock, tick tock...
A poster on Yahoo! posted this and I thought it was interesting. LEAPS-related.
https://register.epo.org/application?number=EP21765012&lng=en&tab=main
"daily short volume"s meaningless intra-day order processing volume. Just MMs doing their job filling orders during the day.
Short INTEREST are open short positions needing to be bought back at some point in the future.
36.83% daily short volume on Tuesday but PPS up 1.12%!
33.15% institutional ownership
36.83% daily short volume on Monday!
9.08 million shares (21.8% of the float) currently shorted
Current borrow fee: 61.9%
Shares available to borrow: 55'000
36.83% of the daily volume has been shorted on Tuesday but the PPS went up 1.12%!! Only 55'000 shares are currently available for shorting (iborrowdesk) and the borrow fee is 61.9%! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...
form 4s coming in let me just steal sushi's thunder and say that they are nothingburgers
you sound mad cheers
it probably had negligible overall effect and you could have sold plenty of covered calls without having to go thru so much effort
but hey we can tell you enjoy spending your time in ahem unique ways
cheers!
Indeed. Worked perfectly.
Cheers!
imagine the confirmation bias required to make a whole kill cvm shorts website
nothing cultish about that either
6 months swing can attract bias either way. Welcome to stocks
I’d rather be on the safe side on sudden news and imminent buyout. Easy logic
These cultists can’t handle a contra opinion. You’re labeled a short if you do.
Only posts with confirmation basis accepted.
It’s textbook and funny to see. Sad actually.
This was a $25+ stock, now $3. They are triggered.
Cheers!
Why would you attack someone for giving truthful information? Why would you suggest I "need to move along" when I've made maybe 2 posts in 2 years here?
There are still about 1,315,722 warrants out there. Many are owned by vulture funds who have shorted against them for years. All but 15,600 expire by the end of the year. About 863,931 expire this summer and 427,035 expire this month.
1. 333,432 warrants at a price of $1.86 with a value of $620,183.52 expire on June 22.
2. 93,603 warrants at a price of $2.80 with a value of $262,088.40 expire on June 30.
3. 120,000 warrants at a price of $9.25 with a value of $1,110,000 expire on July 13.
4. 205,587 warrants at a price of $2.52 with a value of $518,079.24 expire on July 24.
5. 26,000 warrants at a price of $12 with a value of $312,000 expire on August 15.
6. 85,3339 warrants at a price of $3 with a value of $256,017 expire on August 18.
7. 251,761 warrants at a price of $1.65 with a value of $415,405.65 expire on October 30.
8. 200,000 warrants at a price of $2.09 with a value of $418,000. expire on December 18.
When I first came to this board I asked this question below....The stock was trading at $9 then.....Today $3.65??? Hmmmm
Thanks for your input Kpauliukonis.
Not per se. He did say they were in ongoing communication with the FDA.
Cel-Sci Corporation (CVM)
https://www.youtube.com/watch?v=auAihG3rtC4
Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.CANCER - MULTIKINE
Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties. More...INFECTIOUS DISEASES - L.E.A.P.S.(TM)**
L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform. More...* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products
Partnering Philosophy & Corporate Partners
CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of:
CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.
Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.
CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.
Current Corporate Partners:
a. | Agreement Signed August 2008 | ||
b. | Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011. | ||
c. | Revenue Share | ||
d. | Website - http://www.tevapharm.com/ |
a. | Agreement Signed November 2000 | ||
b. | Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008. | ||
c. | Revenue Share | ||
d. | Website - http://www.oep.com.tw/ |
a. | Agreement signed August 2011 | ||
b. | Territory - Argentina and Venezuela | ||
c. | Revenue Share | ||
d. | Website - http://www.gp-pharm.com/ |
Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology. The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.
http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833http://stockcharts.com/freecharts/gallery.html?CVM
http://finance.yahoo.com/q?s=cvm&ql=1
https://frugalnorwegian.com/cvm Insight into CVM P3 Trial Results
https://www.cvmresearch.com Insight into CVM P3 Trial Results & FDA Chances of Approval
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |